The global nuclear imaging equipment market size was valued at USD 7.21 billion in 2025 and is projected to grow from USD 7.44 billion in 2026 to USD 9.56 billion by 2034, registering a CAGR of 3.18% during the forecast period from 2026 to 2034. North America dominated the nuclear imaging equipment market with a market share of 38.6% in 2025.
The global market encompasses the development, production, and adoption of advanced imaging systems that visualize physiological and metabolic processes through the use of radiotracers. This market includes SPECT imaging systems, comprising hybrid SPECT and standalone SPECT platforms, along with PET imaging systems and planar scintigraphy systems that support a wide range of diagnostic pathways. Nuclear imaging technologies are applied across cardiology, oncology, neurology, and other clinical specialties, where they enable precise functional assessment, disease staging, and therapy monitoring. Key end users include hospitals, imaging centers, R&D institutes, and other specialized facilities that utilize these systems for clinical diagnostics, research, and translational applications, driving sustained demand for high-quality nuclear medicine equipment worldwide.
Download a Free Sample To learn more about this report,
A rising trend in the nuclear imaging equipment market is the growing integration of radiomics pipelines into PET and SPECT image interpretation. Research institutions and advanced clinical centers are increasingly extracting quantitative patterns from nuclear imaging datasets to support tumor phenotyping, treatment response evaluation, and metabolic profiling. This shift toward computational image analysis encourages wider adoption of nuclear imaging platforms capable of producing high-detail datasets suitable for radiomics workflows, expanding the analytical applications of PET and SPECT modalities.
The major trend shaping the market is the transition toward compact imaging ecosystems where small footprint cyclotrons, automated tracer synthesizers, and digital PET scanners are integrated into unified clinical workflows. This model supports decentralized tracer production within hospital campuses and enables facilities without large radiopharmacy infrastructure to perform advanced molecular imaging. The rise of compact system layouts drives interest in modular equipment configurations that streamline tracer preparation and imaging procedures within a single operational environment.
A key driver for the market is the expansion of nuclear imaging in therapy response monitoring across oncology, autoimmune disorders, and metabolic diseases. Clinicians are increasingly using PET and SPECT scans to assess early biological changes during treatment rather than relying solely on anatomical imaging. This shift toward functional evaluation encourages higher utilization of advanced scanners and supports procurement of systems capable of delivering quantifiable metabolic and receptor-level insights across diverse patient cohorts.
A major restraint arises from the short half-life of several commonly used PET and SPECT radiotracers, which compresses production, transport, and scanning schedules. Facilities without on-site radiopharmacy infrastructure face additional scheduling constraints, as tracer availability directly affects patient throughput. This time-sensitive workflow structure limits the expansion of nuclear imaging services across centers that lack localized tracer production capabilities, constraining broader equipment utilization.
A growing opportunity emerges from the rapid expansion of radioligand therapy candidates for prostate cancer, neuroendocrine tumors, and rare malignancies. As clinical trials scale globally, high-precision nuclear imaging systems are required to assess tracer biodistribution, quantify receptor expression, and guide patient selection. Rising investment in radioligand therapy development encourages hospitals, research centers, and trial networks to upgrade their PET and SPECT infrastructure, creating new avenues for equipment manufacturers across multiple regions.
The SPECT imaging systems segment dominated the market in 2025, accounting for 58.98% share. This position is driven by rising adoption of advanced SPECT platforms across hospitals upgrading their nuclear medicine departments. As healthcare facilities continue integrating hybrid SPECT configurations, clinicians utilize improved detector layouts and optimized workflow designs to achieve greater diagnostic clarity across cardiac, neurological, and multi-system evaluations, strengthening demand for this product category.
The PET imaging systems segment is projected to grow at the fastest pace during the forecast period with 4.12% CAGR. Growth stems from expanding use of PET/CT scanners in molecular oncology and metabolic imaging, where refined reconstruction algorithms support high-precision quantification. Increasing availability of regional radiotracer production hubs encourages broader installation of PET equipment across both public and private imaging networks, accelerating adoption across new clinical settings.
Request Customizationto receive a tailored report.
The oncology segment dominated the market in 2025, contributing 50.12% share. Expansion of PET-based tumor characterization and widespread use of SPECT/CT for metastasis evaluation supported high uptake of nuclear imaging platforms across cancer centers. As oncology programs integrate more functional imaging pathways into treatment planning and therapy monitoring, procurement of advanced hybrid systems continues to rise across major clinical institutions.
The cardiology segment is expected to record the fastest growth, registering a 4.45% CAGR during the forecast period. Increased adoption of myocardial perfusion imaging and PET-based cardiac assessments contributes to rising installation of SPECT and PET systems in facilities seeking improved visualization of perfusion abnormalities and early-stage cardiac dysfunction, driving strong application expansion in cardiovascular diagnostics.
The hospitals segment dominated the market in 2025 with a 53.24% share. Large public and private hospitals continued to expand nuclear imaging departments, integrating hybrid PET/CT and SPECT/CT systems to support rising diagnostic volumes. Adoption of in-house radiopharmacy units and multi-disciplinary imaging frameworks further strengthened procurement across major hospital ecosystems.
The R&D institutes segment is projected to grow at the fastest rate, posting a 4.68% CAGR during the forecast period. Increased involvement in tracer research, preclinical molecular imaging, and translational science programs has driven the installation of specialized PET and SPECT systems across academic research laboratories and national biomedical centers.
Speak to an Analystto discuss market opportunities.
North America held a major position of 43.78% in the nuclear imaging equipment market in 2025, driven by the expansion of PET tracer production centers across key U.S. medical technology corridors. Regional imaging networks continued integrating advanced PET/CT and SPECT/CT systems through partnerships between research hospitals and domestic device manufacturers, supporting higher utilization of hybrid imaging across oncology and cardiology diagnostics.
In the U.S., growth was influenced by federal investments in molecular imaging research, where academic institutions expanded radiopharmaceutical development programs linked to precision oncology pipelines. The rise in decentralized radiotracer facilities encouraged broader installation of compact cyclotrons and digital PET scanners across tertiary care centers, strengthening market penetration across large hospital networks and specialized imaging clinics.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific is anticipated to register the fastest CAGR of 5.18% during the forecast period, propelled by the surge of molecular imaging research hubs established within national cancer control missions. These programs supported the development of localized PET tracers tailored to region-specific disease patterns, driving sustained adoption of advanced imaging systems across public and private healthcare institutions.
China showed notable growth due to the expansion of provincial radiopharmacy clusters, where PET/CT installation rates increased across tier-two cities. New imaging centers equipped with digital detector systems improved clinical throughput and encouraged broader utilization of nuclear imaging across neurology, endocrinology, and rare disease assessment.
Europe experienced a rise in nuclear imaging equipment adoption, fueled by regional imaging standardization frameworks integrated into cross-border healthcare initiatives. These measures encouraged harmonized installation of PET/CT and SPECT/CT platforms across university hospitals participating in multinational clinical programs.
In France, market expansion was supported by upgrades to national cancer imaging infrastructure, where public hospitals replaced aging gamma cameras with hybrid digital systems. The rollout of facility modernization programs increased demand for advanced reconstruction technologies, expanding domestic procurement of nuclear imaging systems.
Latin America’s nuclear imaging equipment market observed steady development as regional healthcare systems boosted investment in molecular imaging for oncology and cardiac evaluation. Brazil’s expansion of radiopharmaceutical production facilities accelerated the adoption of PET and SPECT platforms across metropolitan hospital networks, supporting wider availability of advanced diagnostic imaging.
Mexico recorded an uptick in installations as private diagnostic chains incorporated new PET/CT systems to address rising demand for early cancer detection. Modernization of radiology centers and partnerships with international imaging vendors strengthened the country’s transition toward higher-resolution nuclear imaging technologies.
The Middle East and Africa region experienced heightened activity in nuclear imaging procurement due to the establishment of new precision-medicine clusters focusing on molecular diagnostics. These initiatives supported the installation of hybrid PET/CT systems and expanded regional radiotracer production capacity.
In the United Arab Emirates, growth was driven by imaging infrastructure expansion within major healthcare free zones, where newly built oncology centers incorporated state-of-the-art PET/CT and SPECT systems. These installations enhanced access to advanced clinical imaging and accelerated adoption across both public and private medical facilities.
The global nuclear imaging equipment market features a moderately consolidated competitive landscape, dominated by a mix of established medical imaging giants and specialized manufacturers focused on PET, SPECT, and hybrid imaging systems. Leading players rely on advanced detector technologies, proprietary reconstruction algorithms, and robust manufacturing capabilities to strengthen their global positioning.
MinFound Medical Systems Co., Ltd. is an emerging competitor gaining visibility in the nuclear imaging equipment market through its advancements in PET/CT and SPECT/CT scanner technologies. The company focuses on cost-efficient, high-performance imaging systems tailored to both developed and emerging markets. Its latest platform, introduced in 2024, features enhanced time-of-flight capabilities and improved digital detectors that deliver superior image clarity with reduced radiation dose. By offering competitively priced solutions, accelerating R&D investments, and expanding its global distribution footprint, MinFound is rapidly establishing itself as a strong new entrant challenging established multinational players in the nuclear imaging equipment ecosystem.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Her work focuses on assessing treatment landscapes, outsourcing models, technology adoption, market access dynamics, regulatory developments, and competitive positioning across healthcare and life sciences industries. Debashree has consistently supported organizations in understanding market gaps, evaluating revenue potential, developing market entry strategies, and shaping expansion plans across complex and fast evolving healthcare markets.
With a strong analytical foundation and structured research approach, she excels at synthesizing large datasets, stakeholder inputs, and market signals into actionable insights that guide strategic decision making. Her healthcare expertise enables her to connect clinical, commercial, and operational developments with business opportunities, helping stakeholders anticipate shifts and capitalize on emerging growth areas. Debashree’s consulting oriented mindset and deep healthcare industry understanding make her a trusted advisor to businesses navigating dynamic and rapidly evolving healthcare markets.
Extremity Tissue Expanders Market Size, Share, Growth, Analysis, 2034
Vaginal Rejuvenation Market Size, Share, Growth, Analysis, 2034
Brachytherapy Market Size, Share, Growth, Analysis, Report, 2034
Assisted Walking Devices Market Size, Share, Growth, 2034
Spirometer Market Size, Share, Growth, Analysis, Report, 2034
Vessel Sealing Devices Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com